C21 Investments (CXXI) AI Stock Analysis

• Market Cap: C$27.61M
• Dividend Yield: N/A
• Average Volume (3M): 41.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: 0.96%
• EPS Growth: -32.11%
• Country: CA
• Employees: 114
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 120,047,810
• 10 Day Avg. Volume: 24,210
• 30 Day Avg. Volume: 41,182
• PEG Ratio: -0.72
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: ―

C21 Investments faces significant challenges in profitability and cash flow, affecting its financial health and valuation. However, recent corporate events including strong third-quarter results and a strategic share repurchase provide a positive outlook, balancing some of the financial and technical weaknesses.

C21 Investments Business Overview & Revenue Model

Company Description

C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States. It offers packaged and wholesale flower, vaporizer pens, cured extracts, edibles, pre-rolls, tinctures, and topicals; and payroll and benefits services. The company was formerly known as Curlew Lake Resources Inc. and changed its name to C21 Investments Inc. in November 2017. C21 Investments Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.

How the Company Makes Money

C21 Investments generates revenue through the cultivation and sale of cannabis products. The company's key revenue streams include retail sales from its branded dispensaries, which offer a range of products directly to consumers, as well as wholesale operations where products are sold to other dispensaries and retailers. Additionally, C21's vertical integration strategy allows it to capture value at multiple stages of the cannabis supply chain, from growing and processing to distribution and retail. Strategic partnerships and acquisitions have also played a role in expanding the company's market reach and enhancing its product offerings, contributing to its overall earnings.

C21 Investments Financial Statement Overview

Summary

C21 Investments is experiencing challenges in revenue generation and profitability, as indicated by declining revenue and negative net profit margins. The balance sheet reflects moderate leverage but a decline in stockholders' equity. Cash flow sustainability is a concern due to a significant decline in free cash flow and negative net income.

Income Statement

C21 Investments shows declining revenue with a negative net profit margin, indicating profitability challenges. The TTM data reflects a challenging year with negative net income. Gross and EBIT margins show some efficiency, but the declining revenue trend from earlier years is concerning.

Balance Sheet

The balance sheet of C21 Investments indicates a moderate debt-to-equity ratio, reflecting manageable leverage. While there is a decline in stockholders' equity, the equity ratio remains relatively stable. However, the company has faced challenges in maintaining positive net income, affecting return on equity.

Cash Flow

Cash flow analysis shows a significant decline in free cash flow in the TTM compared to the previous year, reflecting operational challenges. The operating cash flow to net income ratio is not favorable due to negative net income, indicating potential cash flow management issues.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
28.56M	28.29M	28.89M	32.98M	36.13M	37.71M
	Gross Profit
11.78M	11.15M	13.40M	18.81M	18.65M	13.32M
	EBIT
930.99K	1.47M	3.96M	9.75M	7.52M	-1.18M
	EBITDA
2.96M	3.34M	6.26M	11.68M	12.56M	2.22M
	Net Income Common Stockholders
-4.43M	-3.31M	293.21K	9.95M	-6.11M	-32.56M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
539.65K	2.41M	1.89M	3.07M	6.24M	3.08M
	Total Assets
1.66M	54.53M	58.31M	61.85M	68.81M	61.45M
	Total Debt
0.00	10.72M	12.14M	18.67M	27.30M	36.07M
	Net Debt
-539.65K	8.31M	10.24M	15.60M	21.06M	32.99M
	Total Liabilities
224.80K	23.48M	24.00M	26.87M	43.47M	47.87M
	Stockholders Equity
1.44M	31.05M	34.32M	34.98M	25.34M	13.58M
Cash Flow		Free Cash Flow
-2.58M	5.46M	5.46M	4.27M	9.70M	5.00M
	Operating Cash Flow
1.23M	5.90M	5.90M	6.84M	9.92M	5.51M
	Investing Cash Flow
-3.44M	-390.93K	-390.93K	-1.39M	-1.10M	-4.54M
	Financing Cash Flow
1.94M	-6.68M	-6.68M	-7.84M	-5.70M	-7.10M

C21 Investments Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CXXI, the sentiment is Positive. The current price of 0.23 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.21, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.95 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CXXI.

C21 Investments Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.22B	3.32	-45.04%	2.83%	16.81%	-0.27%
CXXI	49 Neutral	C$27.61M	―	-13.58%	―	0.96%	-32.11%
MILFF		$21.42M	18.83	6.18%	―	―	―
ROMJF		$19.50M	―	-2.68%	―	―	―
VEXTF		$20.72M	―	-24.12%	―	―	―
AVCNF		$21.98M	―	-203.40%	―	―	―
GWAY	44 Neutral	C$26.31M	―	-31.24%	―	44.21%	21.93%